The risk of developing any cancer in LS patients differs widely depending on the mutated MMR gene and sex, with a lifetime risk of developing CRC being higher in MLH1 and MSH2 carriers than in MSH6 and PMS2 carriers and in men than in women [10,11,12,13,14,15,16]. This evidence concerns the gene MLH1 and cancer.